Biocept Stock Price

0.00 (0.0%)
Volume 0
Bid Price 3.82
Ask Price 4.05
News -
Day High


52 Week Range


Day Low
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Biocept Inc BIOC NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 3.90 04:55:11
Open Price Low Price High Price Close Price Prev Close
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 3.90 USD


Draw Mode:

Biocept Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 65.68M 16.84M 16.84M $ 27.46M $ 1.63M -1.70 11.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 465.00k 3.10%

more financials information »

Biocept News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BIOC Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.054.39553.643.84456,541-0.15-3.7%
1 Month3.854.39553.373.78304,6850.051.3%
3 Months3.784.39553.373.87280,2700.123.17%
6 Months4.544.973.263.85725,275-0.64-14.1%
1 Year4.858.383.264.57620,222-0.95-19.59%
3 Years1.038.380.21120.88784375,660,2572.87278.64%
5 Years0.9312.150.1410.96200943,899,4762.97319.35%

Biocept Description

Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.